0000920465-20-000081.txt : 20200602
0000920465-20-000081.hdr.sgml : 20200602
20200602160220
ACCESSION NUMBER: 0000920465-20-000081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200529
FILED AS OF DATE: 20200602
DATE AS OF CHANGE: 20200602
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rolke James
CENTRAL INDEX KEY: 0001693858
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36282
FILM NUMBER: 20936930
MAIL ADDRESS:
STREET 1: 10182 TELESIS COURT, 6TH FLOOR
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO
CENTRAL INDEX KEY: 0000920465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330361285
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4550 TOWNE CENTRE COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-207-4264
MAIL ADDRESS:
STREET 1: 4550 TOWNE CENTRE COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
wf-form4_159112812263735.xml
FORM 4
X0306
4
2020-05-29
0
0000920465
LA JOLLA PHARMACEUTICAL CO
LJPC
0001693858
Rolke James
C/O LA JOLLA PHARMACEUTICAL COMPANY,
4550 TOWNE CENTRE COURT
SAN DIEGO
CA
92121
0
1
0
0
Chief Scientific Officer
Common Stock
2020-05-29
4
A
0
205
4.01
A
81771
D
Stock Option (Right to Buy)
4.72
2020-05-29
4
A
0
205
0
A
2030-05-29
Common Stock
205.0
205
D
These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
/s/ Ryan Murr, as attorney-in-fact for James Rolke
2020-06-02